Drugs / Refametinib
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02168777 | Jun 2014 → Oct 2015 | neoplasm | Bayer | Terminated | No outcome recorded |
| Phase 1 | NCT01925638 | Sep → Dec 2013 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01764828 | Feb 2013 → Dec 2014 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01392521 | Jul 2011 → Feb 2014 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01179295 | Nov 2010 → Apr 2012 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT00610194 | Nov 2007 → Nov 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01251640 | Jan 2011 → Feb 2013 | pancreatic neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1/2 | NCT00785226 | Nov 2008 → Apr 2012 | — | Bayer | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02346032 | Jun 2015 → Sep 2016 | biliary tract cancer | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01915602 | Sep 2013 → Jul 2015 | hepatocellular carcinoma | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT01915589 | Sep 2013 → Oct 2014 | hepatocellular carcinoma | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT01204177 | Dec 2010 → Aug 2011 | hepatocellular carcinoma | Bayer | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Refametinib | “An Open-label Study in Healthy Male Subjects to Assess the Effect of a Strong CYP3A4 Inhibitor, Ketoconazole, on the Pharmacokinetics of Refametinib” NCT01925638 ↗ |
| Known as | BAY 8697661 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1236682 ↗ |
| Known as | BAY86-9766 | “The PI3K (phosphoinositol 3-Kinase) inhibitor Copanlisib and the MEK (mitogen-activated protein kinase) inhibitor Refametinib (BAY86-9766)have both been tested as single agent...” NCT01392521 ↗8“A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable...” PMID 25294897 ↗ Oct 2014 “Refametinib (BAY86-9766)” NCT02168777 ↗ “Refametinib (BAY86-9766)” NCT01915589 ↗ “Refametinib (BAY86-9766)” NCT01764828 ↗ “Refametinib (BAY86-9766)” NCT01915602 ↗ |
| Known as | RDEA119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00785226 ↗ |
| Action | Inhibit | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL1236682 ↗2“Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL1236682 ↗ “RDEA119, A MEK Inhibitor” NCT00610194 ↗ |
| Modality | Small molecule | — CHEMBL1236682 ↗ |
| Route | Oral | “single oral dose of RDEA119 on Day 1” NCT00610194 ↗ |
| Target | MAP2K1 | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL1236682 ↗ |
| Target | MAP2K2 | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL1236682 ↗ |